WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 575820
Description: Gavestinel is a selective glycine antagonist.
MedKoo Cat#: 575820
Chemical Formula: C18H12Cl2N2O3
Exact Mass: 374.0225
Molecular Weight: 375.2
Elemental Analysis: C, 57.62; H, 3.22; Cl, 18.90; N, 7.47; O, 12.79
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Gavestinel; GV 150526; GV 150526X
IUPAC/Chemical Name: 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-((1E)-3-oxo-3-(phenylamino)-1-propenyl)-
InChi Key: WZBNEZWCNKUOSM-VOTSOKGWSA-N
InChi Code: InChI=1S/C18H12Cl2N2O3/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11/h1-9,22H,(H,21,23)(H,24,25)/b7-6+
SMILES Code: OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc3ccccc3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 375.2 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Beardsley PM, Ratti E, Balster RL, Willetts J, Trist D. The selective glycine antagonist gavestinel lacks phencyclidine-like behavioral effects. Behav Pharmacol. 2002 Nov;13(7):583-92. doi: 10.1097/00008877-200211000-00007. PMID: 12409996.
2. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet. 2000 Jun 3;355(9219):1949-54. doi: 10.1016/s0140-6736(00)02326-6. PMID: 10859040.
3. Hoke JF, Dyker AG, Barnaby RJ, Lees KR. Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):867-72. doi: 10.1007/s002280050709. PMID: 10805066.